Mexico City (PRWEB) August 26, 2013
Boryung Pharmaceutical Co. and Stendhal have expanded their cardiovascular partnership with a license and distribution agreement for Boryung’s Arakor Plus, an ARB combined with HTCZ for the treatment of hypertension. Stendhal will launch the product under the brand name Diarakor in 13 Latin American countries.
This agreement expands Stendhal’s cardiovascular portfolio with four additional products based on Boryung’s novel ARB Fimasartan. Stendhal will invest over $40 million in the commercialization of the Fimasartan family of products from Boryung.
Tae-hong Choi, Boryung Pharmaceutical CEO said, "We are interested in Stendhal because it is a company that shares values and a corporate culture of innovation with Boryung. This is an agreement that goes beyond economic interest since it supports a segment of the population with a major illness and whose current therapies have not resulted in a completely effective treatment."
According to Dr. Gerardo Sanchez Mejorada, Medical Director of Stendhal Mexico, "This agreement allows the companies to move closer for the benefit of the population by attacking a problem like hypertension that has been well known as a silent killer and that affects a large proportion of the population".
Boryung and Stendhal share a long-term vision focused on launching innovative cardiovascular products for the benefit of patients in Latin America. With this second license and distribution agreement between the partners, Stendhal’s Cardiovascular franchise is well-positioned to become a market leader in Latin America.
Stendhal is a pharmaceutical company specialized in innovative medicine and high specialty products that offer solutions to diseases threatening human life. The company is specialized in fighting infectious diseases such as HIV/AIDS, hospital acquired infections, conditions affecting central nervous system such as Multiple Sclerosis, and Cardio Metabolic conditions like hypertension. For more information on Stendhal, please visit: http://www.stendhalpharma.com/.
Read the full story at http://www.prweb.com/releases/2013/8/prweb11054147.htm.
Copyright©2012 Vocus, Inc.
All rights reserved